Iovance Biotherapeutics Logo
US4622601007
A2DT49
IOVA

Iovance Biotherapeutics

Loading quotes...

Forecast

The analysts' average price target is €12.34 (+80.15%). The median is €13.65 (+99.27%).

Buy
  15
Hold
  6
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Iovance Biotherapeutics raises annual guidance after strong demand for Amtagvi and Proleukin

    Strong market demand for the cancer therapies Amtagvi (Lifileucel) and Proleukin has led Iovance Biotherapeutics to significantly raise its annual forecast. The company is expanding its TIL therapy platform and broadening the clinical pipeline for additional solid tumors. Despite a weak overall market, investors are drawing the stock higher, signaling company-specific momentum. » More on finanzen.net


  • Iovance raises 2026 revenue forecast after strong demand for Amtagvi

    Iovance raised its 2026 revenue forecast to $410–420 million, supported by rising U.S. demand for Amtagvi and Proleukin. Shorter production times and more than 110 treatment centers are driving growth and pushed the stock up about 10% to a 52-week high. The business remains based on tumor-infiltrating lymphocytes (TIL), which are increasingly entering clinical practice for solid tumors. » More on finanzen.net


  • Iovance Biotherapeutics accelerates revenue growth after successful launch of Amtagvi

    Iovance Biotherapeutics is commercializing Amtagvi, the world’s first approved personalized TIL cell therapy for advanced melanoma. Rapid onboarding of specialized treatment centers and rising patient demand are driving dynamic revenue acceleration in the current fiscal year. Analysts view the first-mover advantage and the successful market entry as drivers for further operational growth. » More on finanzen.net


  • Iovance Biotherapeutics reaches 52-week high at $9.36

    Iovance Biotherapeutics shares rose to a 52-week high of $9.36, delivering a year-to-date return of 215% and nearly a 279% gain over the past year; market capitalization is around $4.2 billion. In Q2 2026 the company reported record revenue of $99.31 million, driven by strong sales of the cancer therapy Amtagvi ($91 million), and an adjusted loss of $0.11 per share, beating expectations. UBS raised its price target to $7.00 (rating: neutral), TD Cowen increased its target to $10.00 and maintained buy; InvestingPro currently considers the stock overvalued. » More on de.investing.com


  • Iovance reports record Q2 revenue and reviews 2026 guidance on strong Amtagvi demand

    Iovance reported record Q2 revenue of about $99.3 million, a 66% year-over-year increase driven by strong Amtagvi sales (U.S. Amtagvi ~$91M) and Proleukin ~$9M. Gross margin improved to 56% on higher volumes, manufacturing efficiencies and cost optimisation, while R&D expenses fell for a fourth consecutive quarter. Management is reviewing its 2026 revenue guidance of $350–370 million with an updated outlook expected in Q3, and continues expanding its treatment network to over 95 centres (forecasting at least 110 by year-end). The company finished the quarter with roughly $304 million in cash and is advancing multiple late‑stage clinical programmes and international regulatory submissions. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics
In 2022, Iovance Biotherapeutics has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Iovance Biotherapeutics had revenue of €107.24M and net profit of -€19.66M
(EUR) September 2026
YoY
Revenue 107.24M 86.57%
Gross profit 64.84M 162.57%
Net profit -19.66M 74.71%
EBITDA -10.74M 83.90%

Fundamentals

Metric Value
Market capitalization
€3.14B
Number of shares
462.66M
52-week high/low
€13.98 - €1.89
Dividends No
Beta
0.76
P/E ratio
-14.08
PEG ratio
-0.15
P/B ratio
4.19
P/S ratio
9.11

Company profile

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Name
Iovance Biotherapeutics
CEO
Frederick G. Vogt
Headquarters San Carlos, ca
USA
Website
Sector
Health Care
Industry
Biotechnology
IPO
10/15/2010
Employees 975

Ticker symbols

Exchange Symbol
NASDAQ
IOVA
London Stock Exchange
0JDK.L
Frankfurt
2LB.F
DĂĽsseldorf
2LB.DU
London
0JDK.L
MĂĽnchen
2LB.MU
🍪

Parqet  uses cookies. Learn more